CervoMed posts smaller-than-expected Q1 net loss

CervoMed

18/05/2026 12:40

Overview

Biotech firm's Q1 net loss narrowed versus analyst expectations

Company reported no grant revenue in Q1, down from $1.9 mln a year earlier

Progress made on planned Phase 3 trial for neflamapimod in dementia with Lewy bodies

Outlook

CervoMed plans to start Phase 3 trial in DLB in second half of 2026, pending financing

Company expects to complete Phase 2a RESTORE trial in stroke and report topline data in H2 2026

Company says cash on hand will fund operations into Q3 2026

Result Drivers

GRANT REVENUE DECLINE - Co said Q1 grant revenue fell to zero from $1.9 mln a year earlier due to completion of RewinD-LB trial and end of related funding

HIGHER R&D EXPENSES - Q1 R&D expenses rose mainly due to increased costs for developing a new formulation and manufacturing process for neflamapimod, as well as ongoing clinical trials and personnel costs

HIGHER G&A EXPENSES - Q1 general and administrative expenses increased due to higher professional fees and personnel costs

Company press release: ID:nGNX7yrhBt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$8 mln
-$9.03 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CervoMed Inc is $21.00, about 510.5% above its May 15 closing price of $3.44

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)